Abstract |
Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq 89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer. Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% and 100%, respectively, as compared to the pretreatment value whereas alkaline phosphatase ( APHOS) had decreased by about 20% (median). The leucocyte and platelet counts were reduced by about 20-35%, without reaching grade greater than or equal to 2 toxicity. Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months. It is concluded that 89Sr represents a worthwhile therapeutic modality in the palliation treatment of patients with hormone resistant prostate cancer, though the biological significance of frequently increasing PSA and decreasing APHOS is not yet completely understood.
|
Authors | S D Fosså, E Paus, M Lochoff, S M Backe, M Aas |
Journal | British journal of cancer
(Br J Cancer)
Vol. 66
Issue 1
Pg. 177-80
(Jul 1992)
ISSN: 0007-0920 [Print] England |
PMID | 1379058
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics
- Biomarkers, Tumor
- Strontium Radioisotopes
- Technetium
- Alkaline Phosphatase
|
Topics |
- Aged
- Alkaline Phosphatase
(blood)
- Analgesics
(therapeutic use)
- Biomarkers, Tumor
(blood)
- Bone Neoplasms
(diagnostic imaging, physiopathology, radiotherapy, secondary)
- Humans
- Injections, Intravenous
- Male
- Pain Management
- Palliative Care
- Prostatic Neoplasms
(diagnostic imaging, physiopathology, radiotherapy)
- Radionuclide Imaging
- Strontium Radioisotopes
(administration & dosage, therapeutic use)
- Technetium
(therapeutic use)
|